Annual Cash & Cash Equivalents:
$771.74M+$431.29M(+126.68%)Summary
- As of today, NAMS annual cash & cash equivalents is $771.74 million, with the most recent change of +$431.29 million (+126.68%) on December 31, 2024.
- During the last 3 years, NAMS annual cash & cash equivalents has risen by +$711.63 million (+1183.84%).
- NAMS annual cash & cash equivalents is now at all-time high.
Performance
NAMS Cash and Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly Cash & Cash Equivalents:
$739.16M-$69.31M(-8.57%)Summary
- As of today, NAMS quarterly cash & cash equivalents is $739.16 million, with the most recent change of -$69.31 million (-8.57%) on June 30, 2025.
- Over the past year, NAMS quarterly cash & cash equivalents has increased by +$308.45 million (+71.62%).
- NAMS quarterly cash & cash equivalents is now -11.39% below its all-time high of $834.19 million, reached on December 31, 2024.
Performance
NAMS Quarterly Cash & Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
NAMS Cash and Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1Y1 Year | +126.7% | +71.6% |
| 3Y3 Years | +1183.8% | +10000.0% |
| 5Y5 Years | +7881.9% | +10000.0% |
NAMS Cash and Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | |
|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +1183.8% | -11.4% | >+9999.0% |
| 5Y | 5-Year | at high | +7881.9% | -11.4% | >+9999.0% |
| All-Time | All-Time | at high | +7881.9% | -11.4% | >+9999.0% |
NAMS Cash and Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $739.16M(-8.6%) |
| Mar 2025 | - | $808.48M(-3.1%) |
| Dec 2024 | $771.74M(+126.7%) | $834.19M(+97.3%) |
| Sep 2024 | - | $422.73M(-1.9%) |
| Jun 2024 | - | $430.71M(-10.5%) |
| Mar 2024 | - | $481.15M(>+9900.0%) |
| Dec 2023 | $340.45M(-27.2%) | - |
| Dec 2022 | $467.73M | - |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $375.50K(-39.0%) |
| Jun 2022 | - | $615.40K(-21.9%) |
| Mar 2022 | - | $788.00K(-35.8%) |
| Dec 2021 | $60.11M(+521.7%) | $1.23M(+93.0%) |
| Sep 2021 | - | $635.60K(-19.5%) |
| Jun 2021 | - | $789.50K(-32.1%) |
| Mar 2021 | - | $1.16M(-14.8%) |
| Dec 2020 | $9.67M | $1.37M |
FAQ
- What is NewAmsterdam Pharma Company N.V. annual cash & cash equivalents?
- What is the all-time high annual cash & cash equivalents for NewAmsterdam Pharma Company N.V.?
- What is NewAmsterdam Pharma Company N.V. annual cash & cash equivalents year-on-year change?
- What is NewAmsterdam Pharma Company N.V. quarterly cash & cash equivalents?
- What is the all-time high quarterly cash & cash equivalents for NewAmsterdam Pharma Company N.V.?
- What is NewAmsterdam Pharma Company N.V. quarterly cash & cash equivalents year-on-year change?
What is NewAmsterdam Pharma Company N.V. annual cash & cash equivalents?
The current annual cash & cash equivalents of NAMS is $771.74M
What is the all-time high annual cash & cash equivalents for NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. all-time high annual cash & cash equivalents is $771.74M
What is NewAmsterdam Pharma Company N.V. annual cash & cash equivalents year-on-year change?
Over the past year, NAMS annual cash & cash equivalents has changed by +$431.29M (+126.68%)
What is NewAmsterdam Pharma Company N.V. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of NAMS is $739.16M
What is the all-time high quarterly cash & cash equivalents for NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. all-time high quarterly cash & cash equivalents is $834.19M
What is NewAmsterdam Pharma Company N.V. quarterly cash & cash equivalents year-on-year change?
Over the past year, NAMS quarterly cash & cash equivalents has changed by +$308.45M (+71.62%)